Cyrus M. Sayehli

Wuerzburg, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Journal: Journal of hematology & oncology

Published: March 25, 2026

Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond.

Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 22, 2026

Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.

Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 24, 2025

Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.

Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.

Journal: Nature

Published: February 25, 2025

Erectile Dysfunction in Patients Treated with Selpercatinib for RET-Altered Thyroid Cancer.

Erectile Dysfunction in Patients Treated with Selpercatinib for RET-Altered Thyroid Cancer.

Journal: Thyroid : official journal of the American Thyroid Association

Published: July 10, 2024

Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.

Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.

Journal: Nature

Published: March 01, 2024

Early clinical trial unit tumor board: a real-world experience in a national cancer network.

Early clinical trial unit tumor board: a real-world experience in a national cancer network.

Journal: Journal of cancer research and clinical oncology

Published: July 16, 2023

Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma.

Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma.

Journal: European journal of nuclear medicine and molecular imaging

Published: November 01, 2022

Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.

Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.

Journal: Immunotherapy

Published: November 11, 2020

Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.

Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.

Journal: Cancer

Published: April 01, 2020

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.

Journal: The Lancet. Oncology

Published: April 12, 2019

Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab.

Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab.

Journal: Blood advances

Published: February 14, 2019

Showing 1-12 of 17

Last Updated: 09/26/2026